The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
April 23rd 2024
The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr. Petrylak on Orteronel Plus Docetaxel in Prostate Cancer
April 9th 2013Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Dr. Sandler on the Unique Characteristics of Radium-223
March 27th 2013Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).
Dr. Gomella on Sequencing Prostate Cancer Therapies
March 25th 2013Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.
At 15 Years, Functional Declines Are Similar Regardless of Therapy Type for Prostate Cancer
March 22nd 201315 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.
Dr. Petrylak on Sipuleucel-T Delaying First Opioid Use
March 21st 2013Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.
New Endocrine Therapies Expand Options for Advanced Prostate Cancer
Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.
Trials Should Test Combinations, Sequences of Novel Treatments for Prostate Cancer
March 18th 2013Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.
Dr. Gomella on Surrogate Endpoints in Prostate Cancer
March 18th 2013Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.
Dr. Antonarakis on Sequencing ADT and Sipuleucel-T
March 7th 2013Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.
Dr. William Oh Discusses Dasatinib in Metastatic CRPC
February 27th 2013William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.
Dr. Antonarakis Describes the TAXYNERGY Trial in mCRPC
February 25th 2013Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.